New Combo Therapy Could Cure Multiple Myeloma Patients

An aggressive bone marrow cancer long considered incurable may finally have met its match.

Researchers at the University of Alabama at Birmingham just proved that combining two existing drugs can keep multiple myeloma patients cancer-free for years. The MajesTEC-3 clinical trial followed 587 patients whose cancer had returned after previous treatments, and the results published in the New England Journal of Medicine are nothing short of remarkable.

More than 83 percent of patients who received the new combination of teclistamab and daratumumab experienced no disease progression after three years. Even more encouraging, cancer recurrences were extremely rare after the first year of treatment, suggesting many patients may actually be cured.

Dr. Luciano Costa, who led the trial, believes we're witnessing a historic turning point. "Every cancer is incurable until it's cured," he says. "We are flipping this from being a cancer that is mostly incurable, to being curable in most patients."

The two-drug combination works by supercharging the immune system. Daratumumab activates T-cells, while teclistamab directs those cells straight to the myeloma, helping them identify and destroy cancer cells. Both drugs have been approved individually for years, but combining them creates something far more powerful than existing therapies.

Multiple myeloma affects more than 36,000 Americans each year. The cancer transforms normal plasma cells into cancerous ones that crowd out healthy cells, leading to bone fractures, anemia, and kidney failure.

The FDA recognized the breakthrough potential immediately, granting priority review status. On March 5, less than four months after results were announced, the combination received full approval.

Sally Herring knows firsthand what this breakthrough means. The Episcopal priest enrolled in the trial when her cancer returned in 2022 after five years in remission. She's now been cancer-free for three years on the new therapy.

"Every month my blood work comes back clear, I thank God for another month of being cancer-free," Herring says. She now uses her experience to help other patients navigate their own cancer journeys.

The Ripple Effect

This approval changes everything for multiple myeloma treatment. Patients who receive the therapy not only live longer and stay disease-free longer, but their quality of life improves dramatically compared to traditional treatments. Costa's team now leads a national trial testing the combination in newly diagnosed patients, where the potential for cure is even greater.

The study shows that patients treated earlier had better immune fitness, suggesting the therapy works best before the immune system becomes weakened by repeated cancer treatments. This could mean catching myeloma early and treating it aggressively with immunotherapy gives patients the best shot at a normal lifespan.

For thousands of families touched by multiple myeloma each year, the word "incurable" may soon become obsolete.